JP2025511401A5 - - Google Patents
Info
- Publication number
- JP2025511401A5 JP2025511401A5 JP2024559034A JP2024559034A JP2025511401A5 JP 2025511401 A5 JP2025511401 A5 JP 2025511401A5 JP 2024559034 A JP2024559034 A JP 2024559034A JP 2024559034 A JP2024559034 A JP 2024559034A JP 2025511401 A5 JP2025511401 A5 JP 2025511401A5
- Authority
- JP
- Japan
- Prior art keywords
- azd5305
- pharmaceutically acceptable
- acceptable salt
- prostate cancer
- darolutamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362612P | 2022-04-07 | 2022-04-07 | |
| US63/362,612 | 2022-04-07 | ||
| PCT/EP2023/059126 WO2023194528A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511401A JP2025511401A (ja) | 2025-04-15 |
| JP2025511401A5 true JP2025511401A5 (enExample) | 2026-04-10 |
Family
ID=86185292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559034A Pending JP2025511401A (ja) | 2022-04-07 | 2023-04-06 | 癌を治療するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250235448A1 (enExample) |
| EP (1) | EP4504180A1 (enExample) |
| JP (1) | JP2025511401A (enExample) |
| KR (1) | KR20240170956A (enExample) |
| CN (1) | CN118973572A (enExample) |
| AU (1) | AU2023248685A1 (enExample) |
| CA (1) | CA3254948A1 (enExample) |
| IL (1) | IL316016A (enExample) |
| MX (1) | MX2024012368A (enExample) |
| TW (1) | TW202404593A (enExample) |
| WO (1) | WO2023194528A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021478A1 (zh) * | 2024-07-23 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 CN CN202380032429.6A patent/CN118973572A/zh active Pending
- 2023-04-06 US US18/853,491 patent/US20250235448A1/en active Pending
- 2023-04-06 IL IL316016A patent/IL316016A/en unknown
- 2023-04-06 CA CA3254948A patent/CA3254948A1/en active Pending
- 2023-04-06 EP EP23719307.3A patent/EP4504180A1/en active Pending
- 2023-04-06 KR KR1020247036943A patent/KR20240170956A/ko active Pending
- 2023-04-06 AU AU2023248685A patent/AU2023248685A1/en active Pending
- 2023-04-06 WO PCT/EP2023/059126 patent/WO2023194528A1/en not_active Ceased
- 2023-04-06 JP JP2024559034A patent/JP2025511401A/ja active Pending
- 2023-04-07 TW TW112112999A patent/TW202404593A/zh unknown
-
2024
- 2024-10-04 MX MX2024012368A patent/MX2024012368A/es unknown